641
Participants
Start Date
May 17, 2010
Primary Completion Date
May 31, 2020
Study Completion Date
September 9, 2021
Varenicline
On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
Bupropion
On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
Placebo
On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
Counseling/Phone Calls
Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
National Institutes of Health (NIH)
NIH
National Institute on Drug Abuse (NIDA)
NIH
Pfizer
INDUSTRY
M.D. Anderson Cancer Center
OTHER